Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 10/20 | 0.74 |
| ▸ | CLK3 | P49761 | 10/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.74 |
| ▸ | CLK1 | P49759 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.69 |
| ▸ | WNT1 | P04628 | 11/20 | 0.69 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15306865 | 0.93 | CLK2 (0.85) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15869079 | 0.92 | CLK2 (0.86) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL15868967 | 0.92 | CLK2 (0.87) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15868973 | 0.92 | CLK2 (0.77) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15371194 | 0.91 | WNT1 (0.67) | CLK2CLK3DYRK1ACLK1GSK3B | |
| SCHEMBL15869090 | 0.91 | WNT1 (0.82) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL15862495 | 0.91 | WNT1 (0.81) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17566016 | 0.90 | WNT1 (0.84) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL15869089 | 0.90 | CLK2 (0.73) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17638245 | 0.90 | WNT1 (0.75) | CLK2CLK3DYRK1ACLK1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2019-11-21 | — | — | US | disclosed |
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2014110086-A2 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352279-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 395/4885CLK3 352/4885DYRK1A 432/4885 |
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 395/4885CLK3 352/4885DYRK1A 432/4885 |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 395/4885CLK3 352/4885DYRK1A 432/4885 |
| US-10654832-B2 | 3-(benzoimidazol-2-YL)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CLK2 395/4885CLK3 352/4885DYRK1A 432/4885 |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CLK2 395/4885CLK3 352/4885DYRK1A 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.